CD40 and pancreatic ductal adenocarcinoma: In pancreatic ductal adenocarcinoma (PDAC), CD40 agonists have demonstrated the ability to reprogram tumor-associated macrophages (TAMs) into tumoricidal cells that facilitate stromal remodeling and promote T cell–independent tumor regression.